Special Issue

Beyond JAK Inhibition: Molecular Pathogenesis and Novel Therapeutic Strategies for the Treatment of Myeloproliferative Neoplasms (MPNs)

Message from the Guest Editor

Because of the shared presence of aberrant JAK/STAT signaling, MPN driver mutations have long been thought of as overlapping in their mechanisms of hematopoietic transformation. However, in recent years, evidence of their distinct molecular and cellular effects has begun to emerge. Understanding the mechanisms underlying the differential molecular pathogenesis of each MPN driver, and exploiting this knowledge to identify unique, targetable dependencies for each mutation, will help to move the needle towards the development of novel, highly specific and potentially curative treatment strategies for MPNs. This Special Issue will highlight work that sheds light on the molecular mechanisms underlying the pathogenesis of mutant *JAK2*, *CALR*, and *MPL*-driven MPNs, and the targetable dependencies unique to each that may represent new therapeutic avenues. This work will provide invaluable insight into the future of MPN treatment, in which the elucidation of basic molecular mechanisms will give way to rationally designed therapies and precision medicine to cure patients without HSCT.

Guest Editor

Dr. Shannon Elisabeth Elf
The Ben May Department for Cancer Research, The University of Chicago, Chicago, IL 60637, USA

Deadline for manuscript submissions

closed (30 April 2024)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/133281

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)